Biologics in the treatment of uveitis

Imrie, Fraser; Dick, Andrew D.

doi:10.1097/icu.0b013e3282f03d42

Cited by 152 publications

(104 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These differences can be supported by differences in the action of the 2 types of agents on membrane-bound TNF, leading to a differential effect on effector T cells and Treg cells. These different mechanisms of action could also explain a better efficacy of mAb therapy in Crohn's disease, in other granulomatous diseases such as sarcoidosis (28), and in uveitis (29).…”

Section: Discussionmentioning

confidence: 99%

Risk of tuberculosis is higher with anti–tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three‐year prospective french research axed on tolerance of biotherapies registry

Tubach

Salmon

Ravaud

et al. 2009

Arthritis & Rheumatism

576

366

View full text Add to dashboard Cite

Objective. Tuberculosis (TB) is associated with anti-tumor necrosis factor (anti-TNF) monoclonal antibody (mAb) therapy, but whether this association is drug-specific remains a concern. Our objective was to describe cases of TB associated with anti-TNF mAb therapy, identify risk factors, and estimate the incidence.Methods. We conducted an incidence study and a case-control analysis to investigate the risk of newly diagnosed TB associated with the use of anti-TNF agents. As part of the French Research Axed on Tolerance of Biotherapies (RATIO) registry, for 3 years we collected cases of TB among French patients receiving anti-TNF mAb therapy for any indication; for each case, 2 patients treated with anti-TNF agents served as control subjects.Results. We collected 69 cases of TB in patients treated for rheumatoid arthritis (n ‫؍‬ 40), spondylarthritides (n ‫؍‬ 18), inflammatory colitis (n ‫؍‬ 9), psoriasis (n ‫؍‬ 1) and Behçet's disease (n ‫؍‬ 1) with infliximab (n ‫؍‬ 36), adalimumab (n ‫؍‬ 28), and etanercept (n ‫؍‬ 5). None of the patients had received correct chemoprophylactic treatment. The sex-and ageadjusted incidence rate of TB was 116.7 per 100,000 patient-years. The standardized incidence ratio (

show abstract

Section: Discussionmentioning

confidence: 99%

Risk of tuberculosis is higher with anti–tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three‐year prospective french research axed on tolerance of biotherapies registry

Tubach

Salmon

Ravaud

et al. 2009

Arthritis & Rheumatism

576

366

View full text Add to dashboard Cite

show abstract

“…Animal models have proven useful in probing cellular mechanisms of disease and as a pre-clinical model to develop treatments for human uveitis. 1 More recently in parallel with features of human disease cell flux, persistence and chronic tissue changes such as angiogenesis have been reported in murine EAU. 2,3 In the C57BL/6 (H-2 b ) mouse model of EAU, immunization with either the human sequence 1-20 or the murine sequence 1-16 of the retinol binding protein-3 (RBP-3; also known as interphotoreceptor retinoidbinding protein) peptide and adjuvants induces EAU, predominantly focused within the posterior segment of the eye.…”

Section: Introductionmentioning

confidence: 99%

“…Human RBP-3 [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20] Peptide (GPTHLFQPSLVLDMAKV LLD) and chicken ovalbumin (OVA) (ISQAVHAAHAEIN EAGR) were synthesized by Sigma-Aldrich (Poole, UK).…”

Section: Reagentsmentioning

confidence: 99%

A novel pathogenic RBP‐3 peptide reveals epitope spreading in persistent experimental autoimmune uveoretinitis

et al. 2015

View full text Add to dashboard Cite

SummaryExperimental autoimmune uveoretinitis (EAU) in the C57BL/6J mouse is a model of non-infectious posterior segment intraocular inflammation that parallels clinical features of the human disease. The purpose of this study was to analyse the immune response to the four murine subunits of retinol binding protein-3 (RBP-3) to identify pathogenic epitopes to investigate the presence of intramolecular epitope spreading during the persistent inflammation phase observed in this model of EAU. Recombinant murine subunits of the RBP-3 protein were purified and used to immunize C57BL/6J mice to induce EAU. An overlapping peptide library was used to screen RBP-3 subunit 3 for immunogenicity and pathogenicity. Disease phenotype and characterization of pathogenic subunits and peptides was undertaken by topical endoscopic fundal imaging, immunohistochemistry, proliferation assays and flow cytometry. RBP-3 subunits 1, 2 and 3 induced EAU in the C57BL/6J mice, with subunit 3 eliciting the most destructive clinical disease. Within subunit 3 we identified a novel uveitogenic epitope, 629-643. The disease induced by this peptide was comparable to that produced by the uveitogenic 1-20 peptide. Following immunization, peptide-specific responses by CD4 + and CD8 + T-cell subsets were detected, and cells from both populations were present in the retinal inflammatory infiltrate. Intramolecular epitope spreading between 629-643 and 1-20 was detected in mice with clinical signs of disease. The 629-643 RBP-3 peptide is a major uveitogenic peptide for the induction of EAU in C57BL/6J mice and the persistent clinical disease induced with one peptide leads to epitope spreading.

show abstract

“…21 Systemically administered infliximab has been used successfully and with few side effects in severe uveitis. 22 TNF-a is involved in cell death during corneal graft rejection, and blocking TNF-a may have a profound …”

Section: Treatment Of Acute Graft Rejection With Antibody-based Theramentioning

confidence: 99%

Antibody-based immunosuppressive agents for corneal transplantation

Thiel

Kaufmann

Coster

et al. 2009

Eye

View full text Add to dashboard Cite

The progress in antibody engineering over the last 20 years has created the tools for the development of novel antibody-based drugs and constructs, such as small antibody fragments, suitable for topical administration. In rheumatology, oncology, transplantation medicine and ophthalmology, therapeutic antibody constructs, and antibody fragments have been responsible for the clinical progress seen over the last decade. Although antibodybased therapies have become a wellestablished immunosuppressive option in solid organ transplantation, there are only very few reports with regard to corneal transplantation. The following review explains some of the important aspects of engineered antibody-based therapeutic agents and summarises the current use of such immunosuppressive therapies in transplantation medicine and corneal transplantation.

show abstract

Biologics in the treatment of uveitis

Cited by 152 publications

References 45 publications

Risk of tuberculosis is higher with anti–tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three‐year prospective french research axed on tolerance of biotherapies registry

Risk of tuberculosis is higher with anti–tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three‐year prospective french research axed on tolerance of biotherapies registry

A novel pathogenic RBP‐3 peptide reveals epitope spreading in persistent experimental autoimmune uveoretinitis

Antibody-based immunosuppressive agents for corneal transplantation

Contact Info

Product

Resources

About